Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

Villar-PiqueA.pdf (530.9 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-07-12

Llicència de publicació

cc by (c) Villar Piqué et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/171400

Plasma YKL-40 in the spectrum of neurodegenerative dementia

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s12974-019-1531-3

Resum

Background: Increased plasma YKL-40 has been reported in Alzheimer's disease (AD), but its levels in other neurodegenerative diseases are unknown. Here, we aimed to investigate plasma YKL-40 in the spectrum of neurodegenerative dementias. Methods: YKL-40 was quantified in the plasma of 315 cases, including healthy controls (HC), neurological disease controls (ND), AD, vascular dementia (VaD), frontotemporal dementia (FTD), sporadic Creutzfeldt-Jakob disease (CJD) and Lewy body dementia (LBD). Diagnostic accuracy in the differential diagnostic context and influence of age and gender was assessed. Results: Highest YKL-40 levels were detected in CJD, followed by LBD, VaD, AD, FTD, ND and HC. YKL-40 was associated to age but not to sex. After controlling for age, YKL-40 was significantly elevated in CJD compared to HC (p<0.001), ND, AD and VaD (p<0.01) and in LBD compared to HC (p<0.05). In CJD, YKL-40 concentrations were significantly higher at late disease stages. Conclusions: Plasma YKL-40 is significantly elevated in CJD regardless of clinical and genetic parameters, with moderate diagnostic accuracy in the discrimination from control cases. Our study discards a potential use of this biomarker in the differential diagnostic context but opens the possibility to be explored as a marker for CJD monitoring.

Matèries

Demència, Malaltia d'Alzheimer

Matèries (anglès)

Dementia, Alzheimer's disease

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

VILLAR PIQUÉ, Anna, et al. Plasma YKL-40 in the spectrum of neurodegenerative dementia. Journal of Neuroinflammation. 2019. Vol. 16. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/171400

Exportar metadades

JSON - METS

Compartir registre